4 years of Skyclarys slows Friedreich’s ataxia progression
Four years of daily treatment with Skyclarys (omaveloxolone) continues to slow the progression of Friedreich’s ataxia (FA) compared to what would be expected in patients without treatment. That’s according to new data from the extension study of the Phase 2 MOXIe clinical trial (NCT02255435), which also showed…